On May 19, 2022 Bio-Techne Corporation (NASDAQ: TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022, at 9:30 a.m. EDT (Press release, Bio-Techne, MAY 19, 2022, View Source [SID1234614901]). A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 19 , 2022 I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, reported that it will hold a call with investors at 8 a.m. EST on May 27th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan (Press release, I-Mab Biopharma, MAY 19, 2022, View Source [SID1234614900]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

I-Mab Conference Call Information

Investors and analysts are invited to join the conference call at 8 a.m. EST on May 27th via Zoom:

Meeting URL: View Source
Meeting ID: 849 6158 6624
Password: 160619

About Uliledlimab (TJD5)

Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

On May 19, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its President and Chief Executive Officer, Rodney Varner, will be providing a virtual overview of the Company’s gene therapies for cancer and diabetes to investors at the following conference in May 2022 (Press release, Genprex, MAY 19, 2022, View Source [SID1234614899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright Global Investment Conference (Virtual and In-Person)
Conference Dates: May 23-26, 2022
Virtual Presentation Date: Available on-demand within the virtual platform for all delegates beginning May 24 at 7 a.m. ET
Presenter: Rodney Varner, Genprex’s President and Chief Executive Officer

Mr. Varner will deliver an overview of the Company’s pioneering gene therapies for cancer and diabetes and will be available for virtual one-on-one meetings with investors through the H.C. Wainwright conference platform

On May 19, 2022 Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, reported that the company will participate virtually in the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022 and in-person in the Jefferies Healthcare Conference taking place June 8-10, 2022 (Press release, Theseus Pharmaceuticals, MAY 19, 2022, View Source [SID1234614898]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Event: H.C. Wainwright Global Investment Conference
Date / Time: Monday, May 23rd – Thursday, May 26th, 2022, on demand
Format: Virtual Presentation

Event: Jefferies Healthcare Conference
Date / Time: Thursday, June 9th, 2022, at 4:30pm ET
Format: Live Fireside Chat

A live webcast will be available in the Events section of the company’s investor relations website at ir.theseusrx.com and archived for 30 days following the presentations.

Management will also be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Theseus management team should contact their H.C. Wainwright or Jefferies representatives.

On May 19, 2022 Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported that the Company will participate in the following upcoming investors’ conferences (Press release, Ryvu Therapeutics, MAY 19, 2022, View Source [SID1234614897]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

UBS Global Healthcare Conference
Format: Corporate overview presentation and one-on-one investor meetings
Date: Monday, May 23rd, 2022, in New York, NY
Presentation Time: 11:30 AM EST

H.C. Wainwright Global Investment Conference
Format: Corporate overview presentation and one-on-one investor meetings
Date: Wednesday, May 25th, 2022, in Miami, FL
Presentation Time: 4:30 PM EST

Erste CEE Technology & Innovation Conference
Format: One-on-one, and group investor meetings
Date: Wednesday, May 25th, 2022, Virtual

IPOPEMA CEE Days
Format: Group investor meeting and Q&A session
Date: Wednesday, June 1st, 2022, Warsaw, Poland
Meeting Time: 2 PM CEST

Pekao Technology Conference
Format: One-on-one investor meetings
Date: Wednesday, June 8th, 2022, Virtual

During the UBS 2022 Global Healthcare Conference and the 2022 H.C. Wainwright Global Investment Conferences, Vatnak Vat-Ho, Chief Business Officer of Ryvu Therapeutics will give a corporate overview and participate in investor meetings. The presentations will be available to conference registrants on-demand. Broader Ryvu management team will be available for meetings during Erste, Ipopema, and Pekao conferences.